Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut Microbiome and Response to Cardiovascular Drugs
Sony Tuteja, Jane F. Ferguson
Circulation Genomic and Precision Medicine (2019) Vol. 12, Iss. 9
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 581
Gut microbiota and cardiovascular disease: opportunities and challenges
Negin Kazemian, Morteza Mahmoudi, Frank Halperin, et al.
Microbiome (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 310
The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases
Estefanía Sánchez-Rodríguez, Alejandro Egea-Zorrilla, Julio Plaza‐Díaz, et al.
Nutrients (2020) Vol. 12, Iss. 3, pp. 605-605
Open Access | Times Cited: 173
Ten things to know about ten cardiovascular disease risk factors
Harold Bays, Pam R. Taub, Elizabeth Epstein, et al.
American Journal of Preventive Cardiology (2021) Vol. 5, pp. 100149-100149
Open Access | Times Cited: 173
The influence of the gut microbiota on the bioavailability of oral drugs
Xintong Zhang, Ying Han, Wei Huang, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 7, pp. 1789-1812
Open Access | Times Cited: 148
Drug-microbiota interactions: an emerging priority for precision medicine
Qing Zhao, Yao Chen, Weihua Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 83
Gut microbiome and risk of ischaemic stroke: a comprehensive Mendelian randomization study
Changjiang Meng, Peizhi Deng, Rujia Miao, et al.
European Journal of Preventive Cardiology (2023) Vol. 30, Iss. 7, pp. 613-620
Closed Access | Times Cited: 54
The Implication of the Gut Microbiome in Heart Failure
Vasile Valeriu Lupu, Anca Adam Răileanu, Cristina Maria Mihai, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1158-1158
Open Access | Times Cited: 46
Microbial Peer Pressure
Rikeish R. Muralitharan, Hamdi Jama, Liang Xie, et al.
Hypertension (2020) Vol. 76, Iss. 6, pp. 1674-1687
Open Access | Times Cited: 101
Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications
Monika Gawałko, Thomas A. Agbaedeng, Arnela Saljic, et al.
Cardiovascular Research (2021) Vol. 118, Iss. 11, pp. 2415-2427
Open Access | Times Cited: 94
A cross-talk between gut microbiome, salt and hypertension
Salma Naqvi, Turky Omar Asar, Vikas Kumar, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 134, pp. 111156-111156
Open Access | Times Cited: 76
Heterogeneity in statin responses explained by variation in the human gut microbiome
Tomasz Wilmanski, Sergey A. Kornilov, Christian Diener, et al.
Med (2022) Vol. 3, Iss. 6, pp. 388-405.e6
Open Access | Times Cited: 45
Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation
Dimitris Tousoulis, Tomasz J. Guzik, Teresa Padró, et al.
Cardiovascular Research (2022) Vol. 118, Iss. 16, pp. 3171-3182
Open Access | Times Cited: 43
Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs
Amina Džidić-Krivić, Jasna Kusturica, Emina Karahmet Sher, et al.
Drug Metabolism Reviews (2023) Vol. 55, Iss. 1-2, pp. 126-139
Open Access | Times Cited: 27
The role of the kynurenine pathway in cardiovascular disease
Yuehang Yang, Xing Liu, Xinyi Liu, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 15
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Targeting the Gut Microbiome to Treat Cardiometabolic Disease
Panagiotis Theofilis, Panayotis K. Vlachakis, Evangelos Oikonomou, et al.
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 2, pp. 25-34
Closed Access | Times Cited: 10
Gut microbiome and cardiovascular disease
Yongzhong Zhao, Zeneng Wang
Current Opinion in Cardiology (2020) Vol. 35, Iss. 3, pp. 207-218
Open Access | Times Cited: 51
Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease
Rebecca L. Walker, Hera Vlamakis, Jonathan Lee, et al.
Genome Medicine (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment
Huiqing Chen, Jinyu Gong, Kai Xing, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 35
Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors
Tao Yang, Xue Mei, Ethel Tackie‐Yarboi, et al.
Hypertension (2022) Vol. 79, Iss. 8, pp. 1591-1601
Open Access | Times Cited: 31
Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases
Yahkub Babatunde Mutalub, Monsurat Abdulwahab, Alkali Mohammed, et al.
Foods (2022) Vol. 11, Iss. 17, pp. 2575-2575
Open Access | Times Cited: 31
Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease
Curtis L. Gabriel, Jane F. Ferguson
Circulation Research (2023) Vol. 132, Iss. 12, pp. 1674-1691
Open Access | Times Cited: 21
Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery
Srinivas Kamath, Andrea M. Stringer, Clive A. Prestidge, et al.
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 10, pp. 1315-1331
Closed Access | Times Cited: 20
Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review
Agata Misera, Igor Łoniewski, Joanna Palma, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top